Leerink Swann restated their market perform rating on shares of Celgene Corp. (NASDAQ:CELG) in a research note issued to investors on Wednesday morning. Leerink Swann currently has a $139.00 price objective on the biopharmaceutical company’s stock.

Several other brokerages have also recently commented on CELG. Vetr cut Celgene Corp. from a strong-buy rating to a buy rating and set a $115.50 price target for the company. in a research note on Monday, October 31st. BTIG Research reaffirmed a buy rating and set a $138.00 target price on shares of Celgene Corp. in a research report on Sunday, August 21st. BMO Capital Markets reaffirmed an outperform rating and set a $141.00 target price on shares of Celgene Corp. in a research report on Monday, October 3rd. JPMorgan Chase & Co. reaffirmed an overweight rating and set a $136.00 target price on shares of Celgene Corp. in a research report on Friday, August 19th. Finally, Jefferies Group reaffirmed a buy rating and set a $134.00 target price on shares of Celgene Corp. in a research report on Monday, October 17th. Four equities research analysts have rated the stock with a hold rating and twenty-seven have given a buy rating to the stock. Celgene Corp. currently has an average rating of Buy and an average price target of $136.77.

Shares of Celgene Corp. (NASDAQ:CELG) opened at 118.51 on Wednesday. The company has a 50 day moving average of $108.88 and a 200 day moving average of $106.73. Celgene Corp. has a 52-week low of $93.05 and a 52-week high of $127.00. The firm has a market capitalization of $91.87 billion, a PE ratio of 45.01 and a beta of 1.71.

Celgene Corp. (NASDAQ:CELG) last announced its quarterly earnings results on Thursday, October 27th. The biopharmaceutical company reported $1.58 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.48 by $0.10. The business earned $2.98 billion during the quarter, compared to analysts’ expectations of $2.84 billion. Celgene Corp. had a return on equity of 70.48% and a net margin of 19.71%. The firm’s quarterly revenue was up 27.8% compared to the same quarter last year. During the same quarter in the previous year, the business posted $1.23 EPS. On average, analysts anticipate that Celgene Corp. will post $5.92 earnings per share for the current fiscal year.

WARNING: “Celgene Corp.’s (CELG) “Market Perform” Rating Reaffirmed at Leerink Swann” was first posted by Daily Political and is owned by of Daily Political. If you are reading this article on another site, it was stolen and republished in violation of U.S. and international copyright & trademark law. The legal version of this article can be viewed at http://www.dailypolitical.com/2016/12/01/celgene-corp-s-celg-market-perform-rating-reaffirmed-at-leerink-swann.html.

In other Celgene Corp. news, major shareholder Corp /De/ Celgene bought 800,150 shares of Celgene Corp. stock in a transaction dated Monday, October 24th. The stock was bought at an average cost of $14.00 per share, for a total transaction of $11,202,100.00. The purchase was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director Michael A. Friedman sold 18,600 shares of Celgene Corp. stock in a transaction that occurred on Wednesday, November 9th. The stock was sold at an average price of $116.10, for a total value of $2,159,460.00. Following the transaction, the director now owns 18,600 shares of the company’s stock, valued at $2,159,460. The disclosure for this sale can be found here. 0.97% of the stock is owned by company insiders.

Several hedge funds and other institutional investors have recently modified their holdings of the company. Arete Wealth Advisors LLC increased its position in shares of Celgene Corp. by 0.3% in the third quarter. Arete Wealth Advisors LLC now owns 3,106 shares of the biopharmaceutical company’s stock valued at $325,000 after buying an additional 10 shares in the last quarter. Park National Corp OH increased its position in shares of Celgene Corp. by 0.4% in the third quarter. Park National Corp OH now owns 3,158 shares of the biopharmaceutical company’s stock valued at $330,000 after buying an additional 12 shares in the last quarter. Proficio Capital Partners LLC increased its position in shares of Celgene Corp. by 0.9% in the third quarter. Proficio Capital Partners LLC now owns 1,627 shares of the biopharmaceutical company’s stock valued at $170,000 after buying an additional 15 shares in the last quarter. Reynders McVeigh Capital Management LLC increased its position in shares of Celgene Corp. by 0.4% in the third quarter. Reynders McVeigh Capital Management LLC now owns 6,265 shares of the biopharmaceutical company’s stock valued at $655,000 after buying an additional 24 shares in the last quarter. Finally, Jolley Asset Management LLC increased its position in shares of Celgene Corp. by 2.1% in the third quarter. Jolley Asset Management LLC now owns 1,240 shares of the biopharmaceutical company’s stock valued at $130,000 after buying an additional 25 shares in the last quarter. Institutional investors own 76.43% of the company’s stock.

Celgene Corp. Company Profile

Celgene Corporation (Celgene) is a biopharmaceutical company. The Company together with its subsidiaries is engaged primarily in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

5 Day Chart for NASDAQ:CELG

Receive News & Ratings for Celgene Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corp. and related companies with MarketBeat.com's FREE daily email newsletter.